ROIV (Roivant Sciences) Insider Ownership: 13.56 % (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROIV Roivant Sciences Ltd ROIV
51 GF Score
Price $34.91
GF Value $11.59
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Insider Ownership?

Roivant Sciences ROIV -0.09% 51 Insider Ownership is 13.56 % as of Jul. 23, 2026. GuruFocus rates ROIV with a GF Score™ of 51/100 and a GF Value™ of $11.59 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Roivant Sciences's insider ownership is 13.56%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Roivant Sciences's Institutional Ownership is 79.66%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Roivant Sciences's Float Percentage Of Total Shares Outstanding is 75.84%.

Roivant Sciences Insider Ownership Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Insider Ownership Chart

Roivant Sciences Historical Data

The historical data trend for Roivant Sciences can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 12.93 14.98 14.91 14.64 14.64 14.11 14.11 13.71 13.59 13.56
ROIV
51GF Score
Roivant Sciences Ltd ROIV
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 13.56 % mean?
Roivant Sciences (ROIV) has a Insider Ownership of 13.56 % as of Jul. 23, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Roivant Sciences and its competitors.
Is Roivant Sciences' Insider Ownership too high?
Roivant Sciences' current Insider Ownership is 13.56 %. Overall, Roivant Sciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Insider Ownership compare to RPRX and BNTX?
Roivant Sciences' Insider Ownership of 13.56 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Roivant Sciences and its competitors. Roivant Sciences's current Insider Ownership is 13.56 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.59, compared to a current price of $34.91 — trading 201.2% above its estimated fair value. The current Insider Ownership is 13.56 %. Roivant Sciences' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Insider Ownership is 13.56 % as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roivant Sciences (ROIV) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of $34.91 is trading 201.2% above its estimated GF Value™ of $11.59. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for ROIV:

  • Insider Ownership: 13.56 %
  • GF Value™: $11.59 vs. price of $34.91 (201.2% above fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roivant Sciences Business Description

Other Exchanges 87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score

Get the complete analysis for ROIV

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.91
Price
$11.59
GF Value